TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22088268

Group type: EXPERIMENTAL
Intervention: Proficiency-based training
Number of subjects: 3

Group type: COMPARATOR
Intervention: Time condition
Number of subjects: 3

Group type: COMPARATOR
Intervention: Repetition condition
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Proficiency condition (experiment 2)
Number of subjects: 3
Study: 21116018

Group type: EXPERIMENTAL
Intervention: Aromatase and 5α-reductase inhibitor (AI) 500 mg once per day for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PL) 500 mg once per day for 8 weeks
Number of subjects: 30
Study: 18182599

Group type: EXPERIMENTAL
Intervention: MenACWY (at 2, 3, and 4 months or 2 and 4 months)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: MenACWY (at 2, 4, and 6 months or 2 and 4 months)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: MenACWY (at 12 months)
Number of subjects: 421

Group type: COMPARATOR
Intervention: MenC (at 2 and 4 months)
Number of subjects: 421
Study: 15654581

Group type: EXPERIMENTAL
Intervention: CE 0.625
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CE 0.625/MPA 2.5
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CE 0.45
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CE 0.45/MPA 2.5
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CE 0.45/MPA 1.5
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CE 0.3
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: CE 0.3/MPA 1.5
Number of subjects: 822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Active treatment (all doses combined)
Number of subjects: 822
Study: 12877450

Group type: EXPERIMENTAL
Intervention: Diskus (inhalation powder)
Number of subjects: 154

Group type: COMPARATOR
Intervention: MDI (inhalation aerosol)
Number of subjects: 154
Study: 10486466

Group type: EXPERIMENTAL
Intervention: Norethindrone 24 hours before gonadotropin-releasing hormone agonist therapy
Number of subjects: 117

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist alone
Number of subjects: 117
Study: 8986438

Group type: EXPERIMENTAL
Intervention: pCMV-CFTR-DOTAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal potential difference measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPO fluorescence assay for halide ion conductance
Number of subjects: 0
Study: 1876434

Group type: EXPERIMENTAL
Intervention: Dorsal column stimulation (DCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study: 29943804

Group type: EXPERIMENTAL
Intervention: Silicone catheter
Number of subjects: 534

Group type: COMPARATOR
Intervention: Latex catheter
Number of subjects: 534
Study: 29021299

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR standard dose (2 108 CFU)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR high dose (2 109 CFU)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Shanchol inactivated cholera vaccine (two doses)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR high dose
Number of subjects: 150
Study: 27231129

Group type: EXPERIMENTAL
Intervention: Loss of chromosome Y (LOY) in blood cells
Number of subjects: 746
Study: 23875876

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSC) from concentrated bone marrow aspirate admixed to the bone graft material
Number of subjects: 7

Group type: COMPARATOR
Intervention: Pure bovine bone material
Number of subjects: 7
Study: 22111662

Group type: EXPERIMENTAL
Intervention: Hydrocortisone pretreatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 19252811

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily for 2 years
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 17086406

Group type: EXPERIMENTAL
Intervention: Meningiomas
Number of subjects: 29
Study: 15243722

Group type: EXPERIMENTAL
Intervention: Conventional TENS (impulse pattern: continuous at 80 Hz; intensity: 10‐30 mA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Acupuncture‐like TENS (impulse pattern: burst at 2 Hz; intensity: 15‐50 mA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham control (stimulation started at 1 mA, increased to no more than 10 mA)
Number of subjects: 66
Study: 12368396

Group type: EXPERIMENTAL
Intervention: Raised AGP (alpha(1)-acid glycoprotein)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Raised CRP (C-reactive protein) and AGP
Number of subjects: 418

Group type: COMPARATOR
Intervention: Infants without acute phase response
Number of subjects: 418
Study: 9637744

Group type: COMPARATOR
Intervention: HTRIG/placebo
Number of subjects: 64

Group type: COMPARATOR
Intervention: HRIG/placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: HTRIG/HDCV
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: HRIG/HDCV
Number of subjects: 64
Study: 8080307

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 31

Group type: COMPARATOR
Intervention: Therapeutic touch placebo
Number of subjects: 31
Study: 2773628

Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: H2 blockers (Ranitidine and Cimetidine)
Number of subjects: 31
Study: 17559

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo I
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo II
Number of subjects: 10
Study: 31642984

Group type: EXPERIMENTAL
Intervention: Phytosterols-enriched soya drink (2 g of phytosterol per day)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Matched soya drink without phytosterols
Number of subjects: 159
Study: 30354023

Group type: EXPERIMENTAL
Intervention: Short-term treatment (12 weeks) with spinal manipulative therapy (SMT) and supervised rehabilitative exercises (SRE)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Long-term management (36 weeks) with spinal manipulative therapy (SMT) and supervised rehabilitative exercises (SRE)
Number of subjects: 182
Study: 29216203

Group type: EXPERIMENTAL
Intervention: 18,000 IU (600 IU/day) of vitamin D3
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 60,000 IU (2000 IU/day) of vitamin D3
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 120,000 IU (4000 IU/day) of vitamin D3
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 25753495

Group type: EXPERIMENTAL
Intervention: High-impact exercise (unilateral hopping exercises) for 12 months, attending 92% of prescribed sessions.
Number of subjects: 50
Study: 23030409

Group type: EXPERIMENTAL
Intervention: Entertainment-education messages with well-integrated educational content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiential involvement and perception of personal relevance in EE messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic message processing
Number of subjects: 0
Study: 21071096

Group type: EXPERIMENTAL
Intervention: Active compounds (aripiprazole, lamotrigine, olanzapine/olanzapine-fluoxetine, quetiapine)
Number of subjects: 3369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3369
Study: 19700897

Group type: EXPERIMENTAL
Intervention: HCD (Hepaticocholecystoduodenostomy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CDJ (Roux-en-y choledochojejunostomy)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 16729779

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray once daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nedocromil sodium nasal spray 3 times daily
Number of subjects: 61
Study: 15250789

Group type: EXPERIMENTAL
Intervention: Context related to athlete or student roles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Role-related contexts (prisoner, churchgoer, factory worker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Role cues (lawyer or prisoner) within the same prison context
Number of subjects: 0
Study: 11174592

Group type: EXPERIMENTAL
Intervention: Topical amoxicillin (3 g per mouthwash rinse)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard prophylaxis with oral amoxicillin (3 g in a single dose)
Number of subjects: 36
Study: 9265424

Group type: EXPERIMENTAL
Intervention: Antiseptic catheter (chlorhexidine and silver sulfadiazine)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control catheter (standard triple-lumen polyurethane catheter)
Number of subjects: 158
Study: 8324872

Group type: EXPERIMENTAL
Intervention: Epirubicin 60 mg/m2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epirubicin 120 mg/m2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epirubicin 150 mg/m2
Number of subjects: 12

Group type: COMPARATOR
Intervention: Epirubicin 75 mg/m2 vs 150 mg/m2
Number of subjects: 12
Study: 3553878

Group type: EXPERIMENTAL
Intervention: Low-dose bromocriptine therapy
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Low-dose levodopa-carbidopa therapy
Number of subjects: 94
Study: 31150439

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28857520

Group type: COMPARATOR
Intervention: 0.5% levobupivacaine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine with 2% lidocaine
Number of subjects: 85
Study: 26494348

Group type: EXPERIMENTAL
Intervention: Hall Technique (HT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional Restorations (CR)
Number of subjects: 132
Study: 23714324

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 21813135

Group type: EXPERIMENTAL
Intervention: PCV7 vaccination with prior nasopharyngeal carriage of serotypes 6B, 19F, or 23F
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV7 vaccination with prior 19F carriage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV7 vaccination with prior 23F carriage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-carriers of serotypes 6B, 19F, and 23F
Number of subjects: 0
Study: 20175430

Group type: EXPERIMENTAL
Intervention: Long-duration (LD) ergometer cycling exercise (90 min)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-intensity (HI) cycling (85% of VO2(max))
Number of subjects: 21

Group type: COMPARATOR
Intervention: Continuous (CON) cycling
Number of subjects: 21
Study: 16684199

Group type: EXPERIMENTAL
Intervention: Factual and storytelling pamphlets
Number of subjects: 113
Study: 15219176

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol 250/50 microg twice daily via DISKUS
Number of subjects: 365

Group type: COMPARATOR
Intervention: Ipratropium bromide/albuterol 36/206 microg four times daily via metered‐dose inhaler
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 365
Study: 11201511

Group type: EXPERIMENTAL
Intervention: Sequential combined oral 17beta-estradiol norethisterone acetate
Number of subjects: 30
Study: 9448650

Group type: EXPERIMENTAL
Intervention: Transmastoid galvanic stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral cathodal stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral anodal stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unipolar stimulation on the side of previous vestibular nerve section
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral stimulation on the intact side
Number of subjects: 0
Study: 7875638

Group type: EXPERIMENTAL
Intervention: Pinacidil (25 mg, sustained-release form)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pinacidil-N-oxide (PO)
Number of subjects: 6
Study: 3277476

Group type: EXPERIMENTAL
Intervention: Topical antibiotics alone (22 patients)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cefoxitin and topical antibiotics (24 patients)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Penicillin, tobramycin, clindamycin, and topical antibiotics (23 patients)
Number of subjects: 69
Study: 29309346

Group type: EXPERIMENTAL
Intervention: Detectable UPLC (≥25 to <1000 μg/l)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Undetectable UPLC (<25 μg/l)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Suboptimal UPLC (≥25 to <1000 μg/l)
Number of subjects: 517
Study: 27769201

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) of mood and retrospective questionnaire (CES-D)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) of energy levels and retrospective questionnaire (CES-D)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group completing only the retrospective questionnaire (CES-D)
Number of subjects: 160
Study: 24237037

Group type: EXPERIMENTAL
Intervention: Individualised dosing of azathioprine (AZA) starting at 1.0 mg/kg/day (if intermediate TPMT) or 2.5 mg/kg/day (if normal TPMT), adjusted to target 6TGN concentrations of 250-400 pmol/8 × 10(8) RBC.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Weight-based dosing of azathioprine (AZA) at 2.5 mg/kg/day.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Individualised dosing of azathioprine (AZA) in per-protocol analysis.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Weight-based dosing of azathioprine (AZA) in per-protocol analysis.
Number of subjects: 50
Study: 24047060

Group type: EXPERIMENTAL
Intervention: Annual screening with fecal occult-blood testing
Number of subjects: 46551

Group type: EXPERIMENTAL
Intervention: Biennial screening with fecal occult-blood testing
Number of subjects: 46551

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 46551
Study: 20447205

Group type: EXPERIMENTAL
Intervention: Peroral pancreatoscopy (PPS) using a small-diameter videoscope and narrow-band imaging (NBI)
Number of subjects: 21
Study: 19083413

Group type: EXPERIMENTAL
Intervention: Increased intake of dietary fiber from fruits/vegetables
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Increased intake of vegetables
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Increased intake of fruits
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Increase of 100 g/d of vegetables
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Increase of 100 g/d of fruits
Number of subjects: 80
Study: 16822123

Group type: EXPERIMENTAL
Intervention: Illusory word paradigm with neighbor‐once‐removed similarity contexts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masked form priming technique with a lexical‐decision task
Number of subjects: 0
Study: 11939988

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Propofol plus 'three‐in‐one' block
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 36
Study: 9716765

Group type: EXPERIMENTAL
Intervention: Warm CO2 pneumoperitoneum (37 degrees C)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cool CO2 pneumoperitoneum (room temperature)
Number of subjects: 26
Study: 7977150

Group type: EXPERIMENTAL
Intervention: High stearic acid diet (7.3% of energy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low stearic acid diet (1.6% of energy)
Number of subjects: 10
Study: 3068604

Group type: EXPERIMENTAL
Intervention: Threshold-related, eccentricity-compensated, spatially adaptive suprathreshold screening program
Number of subjects: 157

Group type: COMPARATOR
Intervention: Full-threshold program on the Humphrey field analyzer
Number of subjects: 157
Study: 31898319

Group type: EXPERIMENTAL
Intervention: Bortezomib, cyclophosphamide, dexamethasone (VCD)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Lenalidomide, cyclophosphamide, dexamethasone (RCD)
Number of subjects: 155
Study: 30508643

Group type: EXPERIMENTAL
Intervention: Vitamin D status (measured as serum 25-hydroxyvitamin D concentration)
Number of subjects: 5110
Study: 28131393

Group type: EXPERIMENTAL
Intervention: Two-week immune response levels of biomarkers
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Demographic information and two-week response levels of different biomarkers
Number of subjects: 201
Study: 23977821

Group type: EXPERIMENTAL
Intervention: Telephone-based coping skills training
Number of subjects: 162
Study: 21362332

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab (1.25 mg/0.05 ml)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg/0.05 ml) combined with triamcinolone acetonide (2 mg/0.05 ml)
Number of subjects: 40
Study: 18950770

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study: 17201798

Group type: EXPERIMENTAL
Intervention: Low-dose hormone replacement therapy (HRT) with continuous oral 17beta oestradiol (1 mg) and norethisterone (0.5 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-dose hormone replacement therapy (HRT)
Number of subjects: 28
Study: 15138953

Group type: EXPERIMENTAL
Intervention: Oral olanzapine (10 mg per day, increased to 20 mg per day by day 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral haloperidol (10 mg per day)
Number of subjects: 0
Study: 11499458

Group type: EXPERIMENTAL
Intervention: Short instruction 'What might this be?'
Number of subjects: 60

Group type: COMPARATOR
Intervention: Long instruction (Killingmo, 1980)
Number of subjects: 60
Study: 9972673

Group type: EXPERIMENTAL
Intervention: Low-dose bedtime NPH insulin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: t.i.d. oral metformin
Number of subjects: 50
Study: 8000960

Group type: EXPERIMENTAL
Intervention: Tap water consumption
Number of subjects: 79

Group type: COMPARATOR
Intervention: Water treated by reverse-osmosis units
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Overall seroprevalence of Norwalk virus
Number of subjects: 79
Study: 2782649

Group type: EXPERIMENTAL
Intervention: Halothane (1.7 MAC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Isoflurane (1.7 MAC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 18
Study: 5321762

Group type: EXPERIMENTAL
Intervention: Isoniazid (5-10 mg per kg of body-weight in one daily dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31954775

Group type: EXPERIMENTAL
Intervention: Dermatophagoides pteronyssinus
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Protease-inactivated Dermatophagoides pteronyssinus
Number of subjects: 100

Group type: COMPARATOR
Intervention: PBS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Human breast milk with Der p 1 and/or OVA
Number of subjects: 100
Study: 31094438

Group type: EXPERIMENTAL
Intervention: Healthy Dads Healthy Kids (HDHK) intervention delivered by trained facilitators
Number of subjects: 495
Study: 28653963

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sham Acupressure
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study: 25961145

Group type: EXPERIMENTAL
Intervention: End-of-treatment self-efficacy
Number of subjects: 1328
Study: 23646342

Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 1.6 W
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 2 W
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 3.2 W
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hydrofluoric acid (HF)
Number of subjects: 100
Study: 21724157

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied to contralateral acupoints LI4 and LI10, stimulation 20 minutes prior to and throughout the SETT
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Meditation throughout the whole experimental procedure
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nontreatment group (control)
Number of subjects: 48
Study: 19344620

Group type: EXPERIMENTAL
Intervention: NasoPore (Stryker Canada)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Merocel (traditional middle meatal spacer)
Number of subjects: 30
Study: 16968566

Group type: EXPERIMENTAL
Intervention: Eszopiclone 2 mg
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 16972680

Group type: EXPERIMENTAL
Intervention: Exercise programs (aerobics, resistance training, walking)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobics, resistance training, walking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise programs
Number of subjects: 0
Study: 12799555

Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg/saquinavir 1200 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atazanavir 600 mg/saquinavir 1200 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ritonavir/saquinavir 400 mg/400 mg twice daily
Number of subjects: 0
Study: 10430107

Group type: EXPERIMENTAL
Intervention: 1200 mg saquinavir (Fortovase soft-gel capsule formulation)
Number of subjects: 12
Study: 7762534

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60 mg, 200,000 IU every 4 months)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study: 2193856

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 x 1 g/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cefotaxime (3 x 1 g/day)
Number of subjects: 41
Study: 307155

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 30773747

Group type: EXPERIMENTAL
Intervention: CHM-diet (2% Chinese herbal medicine)
Number of subjects: 6

Group type: COMPARATOR
Intervention: MH-diet (mixed hay, control)
Number of subjects: 6
Study: 28128473

Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (HA) injections (HAnox-M or BioHA), 3 weekly injections
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (HA) injections (HAnox-M or BioHA)
Number of subjects: 166
Study: 26653260

Group type: EXPERIMENTAL
Intervention: Two sessions of glaucoma educational intervention (60-90 minutes each)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 165